Introduction
Septic shock is one of the leading and increasing causes of morbidity and mortality in critically ill patients [1, 2] . Activation of the innate immune system and uncontrolled inflammatory reactions has been considered to play a central role in the pathogenesis of this devastating disorder [1, 2] . Despite significant advances in supportive care and availability of potent, broad-spectrum antibiotics, overall mortality rate due to septic shock is still high [3] . Therefore, therapeutic interventions for the management of septic shock present a significant clinical challenge, and development of novel therapeutic strategy is actually desired.
Statins inhibit 3-hydroxy-methylglutaryl coenzyme A reductase, a rate-limiting enzyme for cholesterol synthesis and are now one of the most popular drugs for the treatment of dyslipidemia [4] [5] [6] . A large body of evidence has suggested that statins reduce the risk of future cardiovascular events in humans by lowering low-density lipoprotein cholesterol level [4] [5] [6] . Furthermore, although large randomized controlled trials are missing and that pleiotropic actions of statins are rapid, but may be prone to tolerance [7] , statins have been shown to provide protective effects in high risk-patients for cardiovascular disease in a cholesterol-lowering independent manner [8] [9] [10] [11] [12] [13] [14] . Therefore, anti-inflammatory and immunomodulatory properties of statins could be applicable in inflammatory disorders such as septic shock [14] .
Endotoxin, which consists of lipopolysaccharides, is an outer membrane component of gram-negative bacteria and an important pathogenic substance to trigger septic shock by producing a variety of inflammatory mediators [15] . Multi-centered studies showed that hemoperfusion with polymyxin B-immobilized polystyrene fiber (PMX-F), a medical device that aims to remove circulating endotoxin by adsorption [15] , was shown to be a safe and effective therapy in ameliorating cardiac and renal dysfunction due to severe sepsis or septic shock [16, 17] . However, whether clinical benefits of statin use and PMX-F therapy in patients with septic shock are observed independently remains unknown.
We examined in a retrospective cohort study whether pre-existing statin therapy and removal of endotoxin by hemoperfusion with PMX-F at the time of admission were associated with decreased overall 28-day mortality in septic shock patients. We also examined in multivariate stepwise regression analysis if pre-existing statin use and PMX-F therapy were separately and independently correlated with 28-day survival in septic shock subjects.
Patients and methods

Subjects
Consecutive 173 patients with septic shock (71.2±10.7 years old, 115 male and 58 female) were included in the present study. The criterion of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference was used for the diagnosis of septic shock [18] . Patients with chronic liver disease, chronic kidney disease, neoplasms or pregnancy, taking steroids, immunosuppressive agents or non-steroidal anti-inflammatory drugs were excluded from the study. Although age range of participants was relatively wide, patients younger than 20 years old or older than 85 years old were also excluded from the study. Subjects who have received statins for more than 1 month at the time of septic shock were assigned to statin group (n=63; 39 pitavastatin, 6 pravastatin, 18 atorvastatin). At the time of admission, most patients have already received intensive therapies: e.g. mechanical ventilation, administration of antibiotics (penicillins, cephalosporins, quinolones, carbapenem, etc.) and/or vasopressor agents. Hemoperfusion with PMX-F was performed in 102 patients whose consent was obtained at the admission of our hospital. Endotoxin removal by PMX-F treatment was repeated twice, separated by an interval of 24 hours as described previously [19] . Direct hemoperfusion was carried out for 2 hours at a flow rate of 80-100 ml/min. Severity of disease was evaluated clinically by both Sequential Organ-Failure Assessment (SOFA) score and Acute Physiology and Chronic Health Evaluation (APACHE) II score according to the methods described previously [20, 21] . Non-survivors were defined as patients who died up to 28 days after admission. The study protocol was approved by the local ethical committee of Shinmatsudo Central General Hospital, and informed consent was obtained from all the alert subjects or first-degree relatives of drowsy patients. The study complied with the principles of the Helsinki Declaration.
Data collections
Blood pressure (BP) was measured in supine position at the time of admission, and peripheral blood samples (20 ml) were collected for the determinations of biochemical variables. Each sample was stored at -80°C before the assays. Serum endotoxin levels were determined by an Endospecy test (Seikagaku-Kogyo Co., Ltd., Osaka, Japan) [16] . Other biochemistries were measured at a laboratory of Shinmatsudo Central General Hospital as described previously [19, 22] .
Statistical analysis
Data are expressed as mean ± standard deviation (SD). Mann-Whitney's U test or Pearson chi test was used for comparisons of the parameters between stain group and non-statin group and between survivors and non-survivors. A correlation between 28-day survival and other clinical and biochemical variables was determined by a linear regression analysis. To determine independent determinants of 28-day survival of septic shock patients, multiple stepwise regression analysis was performed. Statistical significance was defined as p<0.05. All statistical analyses were performed with the use of the SPSS system (SPSS Japan Inc., IBM company, Tokyo, Japan).
Results
As shown in Table 1 , among the 173 septic shock patients, a total of 63 patients (36.4 %) have already received statins at the time of admission. Compared with stain non-use group, diastolic BP, heart rate, hemoglobin (Hb), endotoxin and high-density lipoprotein-cholesterol (HDL-Chol) were significantly higher in statin use group, while white blood cell (WBC) number, C-reactive protein (CRP), APACHE II score, SOFA score, total cholesterol (T-Chol), low-density lipoprotein-cholesterol (LDL-Chol) and triglycerides were lower. There were no significant differences of intensive supportive therapies such as vasopressors, PMX treatment or ventilation between the two groups. Table 2 shows the baseline characteristics of survivors and non-survivors of our patients. Albumin, endotoxin, HDL-Chol, rate of statin use and PMX treatment were higher, while WBC number, creatinine, CRP, SOFA score, T-Chol, LDL-Chol and rate of ventilation were lower in survivors compared with non-survivors. Duration of statin use was also longer in survivors than in non-survivors. Table 2 . Baseline characteristics of survivors and non-survivors.
As shown in Table 3 , WBC number (inversely), albumin, creatinine (inversely), CRP (inversely), endotoxin, SOFA score (inversely), T-Chol (inversely), LDL-Chol (inversely), HDL-Chol, statin use, PMX treatment and ventilation (inversely) were associated with 28-day survival in our subjects. Because these parameters could be closely correlated with each other, to determine independent determinants of 28-day survival, multiple stepwise regression analysis was performed. This analysis showed that albumin, creatinine (inversely), statin use, PMX treatment and HDL-Chol were independently correlated to 28-day survival in septic shock patients (R 2 =0.464) ( Table 4 ).
Discussion
As far as we know, there were five retrospective, nonmatched cohort studies to examine the effect of preexisting statin use on mortality of septic shock patients [23] [24] [25] [26] [27] . However, there was some controversy about the effects of pre-existing statin use on clinical outcomes of septic shock patients. Indeed, two studies have shown that stain use was associated with decreased 30-day mortality or infection-related mortality in septic shock patients [23, 24] , while the other two studies showed no beneficial effects of statin use on survival of septic shock [25, 26] . In the remaining one, stain use was associated with poor prognosis and increased hospital mortality in septic shock patients [27] . The difference of subject number, population and ethnicity could account for the conflicting results of studies mentioned. Furthermore, since removal of endotoxin by hemoperfusion with PMX-F could have favorable effects on mortality risk in septic shock patients [28, 29] , the presence or absence of PMX treatment may also confound the clinical utility of statin use in these subjects. Therefore, we examined here in a retrospective cohort study whether pre-existing statin therapy at the time of admission was independently associated with decreased overall 28-day mortality in septic shock patients. In the present study, we found that besides well-known prognostic markers for septic shock, including albumin and creatinine [30, 31] , statin use and PMX treatment were separately and independently associated with decreased 28-day mortality rate in septic shock patients. Statins have been shown to possess antiinflammatory, anti-oxidative, cardioprotective properties in humans [8] [9] [10] [11] [12] [13] [14] . Given the crucial role of uncontrolled immune and inflammatory reactions in septic shock [1, 2] , the present study suggests that statin use could contribute to blunt the process of septic shock through its immunomodulatory pleiotropic actions. Endotoxin plays an important role in the development and progression of septic shock by producing pro-inflammatory cytokines and activating the complement system [15] . In this study, since PMX treatment was independently associated with favorable clinical outcomes of septic shock patients, endotoxin removal by PMX treatment may also be a potential therapeutic target for the treatment of septic shock. Pre-existing statin use may not be enough for controlling the endotoxin-evoked inflammatory reactions in septic shock. In the present study, baseline endotoxin levels were higher in survivors than in non-survivors (Table 1) . Since PMX treatment, but not baseline endotoxin level, was correlated with 28-day survival in multivariate analysis (Table 4) , patients with increased endotoxin values may receive more PMX-F treatment. In this study, high HDL-Chol level was associated with decreased 28-day mortality of our septic shock patients, which was independent of statin use. Since HDLChol was shown to have anti-inflammatory and antioxidative capacities in vivo [32, 33] , immunomodulatory properties of HDL-Chol may also play a protective role against septic shock. Further large clinical, randomized, prospective study is needed to evaluate whether preexisting statin use and/or PMX-F treatment is associated with favorable outcome in septic shock patients.
Limitations
Pleiotropic actions of statins are rapid [7] . Therefore, at least 1 month of statin pre-use is not necessarily needed to examine its pleiotropic actions in septic shock patients. Furthermore, we can not completely exclude the possibility that immunomodulatory effects of antibiotics could confound the present findings, although most patients have already received various types of antibiotics (penicillins, cephalosporins, quinolones, carbapenem, etc.) at the time of admission.
